BD Receives FDA Approval for New Automated Cervical Cancer Screening System

FRANKLIN LAKES, N.J., March 7, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) approval for its  BD Totalys™ MultiProcessor and BD Totalys™ SlidePrep instruments.

Together with the BD FocalPoint™ SlideProfiler, these innovations comprise the full BD Totalys System, which further automates slide preparation, imaging and review for use in cervical cancer screening, as well as providing ancillary testing aliquot capability. Increasing automation in the laboratory helps to reduce the potential for human error and increases lab workflow efficiency. The BD™ DataLink middleware connects the BD Totalys instruments to a Laboratory Information System, improving laboratory efficiency while providing continuous sample tracking to ensure patients get the right results.

The BD Totalys System combined with the BD SurePath™ liquid-based Pap test offers an improved automated process for cervical cancer screening laboratories versus current methods.

"We are very pleased to introduce the BD Totalys System in the United States," said Doug White, vice president and general manager, Women's Health & Molecular Diagnostics. "The BD Totalys System provides clinical laboratories with a highly customizable, automated liquid-based cytology solution to help improve laboratory efficiency, enhance sample tracking and maintain high quality diagnostic results."

The BD Totalys System provides a balance of automation and flexibility to help meet the needs of medium and high throughput cervical cancer screening labs by increasing workflow efficiency, reducing technician hands-on time and repetitive motion and improving usability, user safety, overall process quality and functionality.

About BD
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance cellular studies and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit www.bd.com.

Contact:

Matthew Coppola
BD Public Relations
201.847.7330
Matthew_R_Coppola@bd.com

Monique N. Dolecki
BD Investor Relations
201.847.5378
Monique_Dolecki@bd.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bd-receives-fda-approval-for-new-automated-cervical-cancer-screening-system-300230930.html

SOURCE BD (Becton, Dickinson and Company)